Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

Gerard J. Criner; Jean Bourbeau; Rebecca L. Diekemper; Daniel R. Ouellette; Donna Goodridge; Paul Hernandez; Kristen Curren; Meyer S. Balter; Mohit Bhutani; Pat G. Camp; Bartolome R. Celli; Gail Dechman; Mark T. Dransfield; Stanley B. Fiel; Marilyn G. Foreman; Nicola A. Hanania; Belinda K. Ireland; Nathaniel Marchetti; Darcy D. Marciniuk; Richard A. Mularski; Joseph Ornelas; Jeremy D. Road; Michael K. Stickland

doi:10.1378/chest.14-1677

Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

Gerard J. Criner, Jean Bourbeau, Rebecca L. Diekemper, Daniel R. Ouellette, Donna Goodridge, Paul Hernandez, Kristen Curren, Meyer S. Balter, Mohit Bhutani, Pat G. Camp, Bartolome R. Celli, Gail Dechman, Mark T. Dransfield, Stanley B. Fiel, Marilyn G. Foreman, Nicola A. Hanania, Belinda K. Ireland, Nathaniel Marchetti, Darcy D. Marciniuk, Richard A. MularskiJoseph Ornelas, Jeremy D. Road, Michael K. Stickland

Research output: Contribution to journal › Article › peer-review

59 Citations (Scopus)

Original language	English
Pages (from-to)	883-893
Number of pages	11
Journal	Chest
Volume	147
Issue number	4
DOIs	https://doi.org/10.1378/chest.14-1677
Publication status	Published - Apr 2015

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1378/chest.14-1677

Cite this

Criner, G. J., Bourbeau, J., Diekemper, R. L., Ouellette, D. R., Goodridge, D., Hernandez, P., Curren, K., Balter, M. S., Bhutani, M., Camp, P. G., Celli, B. R., Dechman, G., Dransfield, M. T., Fiel, S. B., Foreman, M. G., Hanania, N. A., Ireland, B. K., Marchetti, N., Marciniuk, D. D., ... Stickland, M. K. (2015). Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest, 147(4), 883-893. https://doi.org/10.1378/chest.14-1677

Criner, GJ, Bourbeau, J, Diekemper, RL, Ouellette, DR, Goodridge, D, Hernandez, P, Curren, K, Balter, MS, Bhutani, M, Camp, PG, Celli, BR, Dechman, G, Dransfield, MT, Fiel, SB, Foreman, MG, Hanania, NA, Ireland, BK, Marchetti, N, Marciniuk, DD, Mularski, RA, Ornelas, J, Road, JD & Stickland, MK 2015, 'Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline', Chest, vol. 147, no. 4, pp. 883-893. https://doi.org/10.1378/chest.14-1677

@article{d78e75cd219d417c8da93c402c32d231,

title = "Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline",

author = "Criner, {Gerard J.} and Jean Bourbeau and Diekemper, {Rebecca L.} and Ouellette, {Daniel R.} and Donna Goodridge and Paul Hernandez and Kristen Curren and Balter, {Meyer S.} and Mohit Bhutani and Camp, {Pat G.} and Celli, {Bartolome R.} and Gail Dechman and Dransfield, {Mark T.} and Fiel, {Stanley B.} and Foreman, {Marilyn G.} and Hanania, {Nicola A.} and Ireland, {Belinda K.} and Nathaniel Marchetti and Marciniuk, {Darcy D.} and Mularski, {Richard A.} and Joseph Ornelas and Road, {Jeremy D.} and Stickland, {Michael K.}",

note = "Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Bourbeau received government grants for conducting the longitudinal population-based Canadian Cohort Obstructive Lung Disease (CanCOLD) study from the Canadian Institute of Health Research (CIHR) Rx&D collaborative program (AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Merck Sharp & Dohme Corp, Nycomed, Novartis AG), Canadian Respiratory Research Network, Respiratory Health Network of the Fonds de recherche du Qu{\'e}bec-Sant{\'e}, and Research Institute of the McGill University Health Centre. Ms Diekemper is a codeveloper of the DART (Document and Appraisal Review Tool), which was used in the AECOPD Guideline to assess the quality of the systematic reviews that informed some of the recommendations. Dr Hernandez reports that his institution has received pharmaceutical company grant monies for research studies on which he has been an investigator, including CSL Behring, Boehringer Ingelheim GmbH, and Grifols International SA. His institution also has received grant monies for research studies for which he has been an investigator, including CIHR and Lung Association of Nova Scotia. He has participated in speaking activities, industry advisory committees, and other activities related to industry sources with the following pharmaceutical companies: Actelion Pharmaceuticals US, Inc; Almirall, SA; AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Grifols; Intermune; Merck Sharp & Dohme Corp; and Novartis AG. Dr Balter has served over the past 3 years on advisory boards for and has presented at continuing education meetings for Almirall, SA; AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Merck Frosst Canada Inc; Novartis AG; and Takeda Pharmaceutical Company Limited. Dr Bhutani receives university grant money, pharmaceutical grant money, grant money from government organizations in Canada and participates in speakers bureaus and speaks publicly on the topic of AECOPD. Dr Camp has received operating grant funding from CIHR, Canadian Lung Association, and Physiotherapy Foundation of Canada. She has received research infrastructure funding from the Canadian Foundation of Innovation and the British Columbia Lung Association and a scholar award from the Michael Smith Foundation of Health Research. She has received honoraria for speaking engagements from the Canadian Lung Association and the University of British Columbia Respiratory Division. Dr Celli's division has received grants from AstraZeneca to complete research studies. He has served on an advisory board or as a consultant to GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Almirall, SA; AstraZeneca; Takeda Pharmaceutical Company Limited; and Novartis AG. Neither he nor any member of his family has shares or interest in any company. Dr Celli has not received or had any relationship with tobacco money. Dr Dechman speaks to health professionals about the management of COPD, including AECOPD, but does not gain financially from doing so. Dr Dransfield has served as a consultant for GlaxoSmithKline plc; Boehringer Ingelheim GmbH; and Ikaria, Inc. His institution has received research grant support from the American Heart Association; National Heart, Lung, and Blood Institute; GlaxoSmithKline plc; and Forest Laboratories, Inc, and has received contracted support for enrollment in clinical trials from Aeris; Boehringer Ingelheim GmbH; Boston Scientific Corporation; Janssen Biotech, Inc (formerly Centocor Biotech, Inc); GlaxoSmithKline plc; Forest Laboratories, Inc; Otsuka America Pharmaceutical, Inc; Pearl Therapeutics Inc; Pfizer, Inc; PneumRx, Inc; and Pulmonx. Dr Fiel has received grant support from the Cystic Fibrosis Foundation and grants for clinical trials from Vertex Pharmaceuticals Incorporated, Gilead, Novartis AG, and PTC Therapeutics. Dr Foreman is PI for the Forest ASCENT COPD study (LAS-MD-45). Dr Hanania serves as a consultant to Boehringer Ingelheim GmbH; Sunovion Pharmaceuticals Inc; Novartis AG; Mylan Inc; Pearl Therapeutics Inc; and Pfizer, Inc. Her institution receives grant support on her behalf from GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Pfizer, Inc; Pearl Therapeutics Inc; and Sunovion Pharmaceuticals Inc. Dr Marchetti has served as principal investigator for a pharmaceutical-funded clinical trial with GlaxoSmithKline plc. Dr Marciniuk has provided consultation for Health Canada, the Public Health Agency of Canada, and the Saskatoon Health Region. He has received research funding (all held and managed by the University of Saskatchewan) from AstraZeneca; Boehringer Ingelheim GmbH; CIHR; Forest Laboratories Inc; the Lung Association of Saskatchewan; Novartis AG; Pfizer, Inc; Saskatchewan Health Research Foundation; and Schering-Plough Corporation. He holds fiduciary positions with the American College of Chest Physicians, the Chest Foundation, and the Lung Health Institute of Canada. Drs Criner, Ouellette, Goodridge, Ireland, Mularski, Road, and Stickland; Ms Curren; and Mr Ornelas have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. ",

year = "2015",

month = apr,

doi = "10.1378/chest.14-1677",

language = "English",

volume = "147",

pages = "883--893",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "4",

}

TY - JOUR

T1 - Executive Summary

T2 - Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

AU - Criner, Gerard J.

AU - Bourbeau, Jean

AU - Diekemper, Rebecca L.

AU - Ouellette, Daniel R.

AU - Goodridge, Donna

AU - Hernandez, Paul

AU - Curren, Kristen

AU - Balter, Meyer S.

AU - Bhutani, Mohit

AU - Camp, Pat G.

AU - Celli, Bartolome R.

AU - Dechman, Gail

AU - Dransfield, Mark T.

AU - Fiel, Stanley B.

AU - Foreman, Marilyn G.

AU - Hanania, Nicola A.

AU - Ireland, Belinda K.

AU - Marchetti, Nathaniel

AU - Marciniuk, Darcy D.

AU - Mularski, Richard A.

AU - Ornelas, Joseph

AU - Road, Jeremy D.

AU - Stickland, Michael K.

N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Bourbeau received government grants for conducting the longitudinal population-based Canadian Cohort Obstructive Lung Disease (CanCOLD) study from the Canadian Institute of Health Research (CIHR) Rx&D collaborative program (AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Merck Sharp & Dohme Corp, Nycomed, Novartis AG), Canadian Respiratory Research Network, Respiratory Health Network of the Fonds de recherche du Québec-Santé, and Research Institute of the McGill University Health Centre. Ms Diekemper is a codeveloper of the DART (Document and Appraisal Review Tool), which was used in the AECOPD Guideline to assess the quality of the systematic reviews that informed some of the recommendations. Dr Hernandez reports that his institution has received pharmaceutical company grant monies for research studies on which he has been an investigator, including CSL Behring, Boehringer Ingelheim GmbH, and Grifols International SA. His institution also has received grant monies for research studies for which he has been an investigator, including CIHR and Lung Association of Nova Scotia. He has participated in speaking activities, industry advisory committees, and other activities related to industry sources with the following pharmaceutical companies: Actelion Pharmaceuticals US, Inc; Almirall, SA; AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Grifols; Intermune; Merck Sharp & Dohme Corp; and Novartis AG. Dr Balter has served over the past 3 years on advisory boards for and has presented at continuing education meetings for Almirall, SA; AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline plc; Merck Frosst Canada Inc; Novartis AG; and Takeda Pharmaceutical Company Limited. Dr Bhutani receives university grant money, pharmaceutical grant money, grant money from government organizations in Canada and participates in speakers bureaus and speaks publicly on the topic of AECOPD. Dr Camp has received operating grant funding from CIHR, Canadian Lung Association, and Physiotherapy Foundation of Canada. She has received research infrastructure funding from the Canadian Foundation of Innovation and the British Columbia Lung Association and a scholar award from the Michael Smith Foundation of Health Research. She has received honoraria for speaking engagements from the Canadian Lung Association and the University of British Columbia Respiratory Division. Dr Celli's division has received grants from AstraZeneca to complete research studies. He has served on an advisory board or as a consultant to GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Almirall, SA; AstraZeneca; Takeda Pharmaceutical Company Limited; and Novartis AG. Neither he nor any member of his family has shares or interest in any company. Dr Celli has not received or had any relationship with tobacco money. Dr Dechman speaks to health professionals about the management of COPD, including AECOPD, but does not gain financially from doing so. Dr Dransfield has served as a consultant for GlaxoSmithKline plc; Boehringer Ingelheim GmbH; and Ikaria, Inc. His institution has received research grant support from the American Heart Association; National Heart, Lung, and Blood Institute; GlaxoSmithKline plc; and Forest Laboratories, Inc, and has received contracted support for enrollment in clinical trials from Aeris; Boehringer Ingelheim GmbH; Boston Scientific Corporation; Janssen Biotech, Inc (formerly Centocor Biotech, Inc); GlaxoSmithKline plc; Forest Laboratories, Inc; Otsuka America Pharmaceutical, Inc; Pearl Therapeutics Inc; Pfizer, Inc; PneumRx, Inc; and Pulmonx. Dr Fiel has received grant support from the Cystic Fibrosis Foundation and grants for clinical trials from Vertex Pharmaceuticals Incorporated, Gilead, Novartis AG, and PTC Therapeutics. Dr Foreman is PI for the Forest ASCENT COPD study (LAS-MD-45). Dr Hanania serves as a consultant to Boehringer Ingelheim GmbH; Sunovion Pharmaceuticals Inc; Novartis AG; Mylan Inc; Pearl Therapeutics Inc; and Pfizer, Inc. Her institution receives grant support on her behalf from GlaxoSmithKline plc; Boehringer Ingelheim GmbH; Pfizer, Inc; Pearl Therapeutics Inc; and Sunovion Pharmaceuticals Inc. Dr Marchetti has served as principal investigator for a pharmaceutical-funded clinical trial with GlaxoSmithKline plc. Dr Marciniuk has provided consultation for Health Canada, the Public Health Agency of Canada, and the Saskatoon Health Region. He has received research funding (all held and managed by the University of Saskatchewan) from AstraZeneca; Boehringer Ingelheim GmbH; CIHR; Forest Laboratories Inc; the Lung Association of Saskatchewan; Novartis AG; Pfizer, Inc; Saskatchewan Health Research Foundation; and Schering-Plough Corporation. He holds fiduciary positions with the American College of Chest Physicians, the Chest Foundation, and the Lung Health Institute of Canada. Drs Criner, Ouellette, Goodridge, Ireland, Mularski, Road, and Stickland; Ms Curren; and Mr Ornelas have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

PY - 2015/4

Y1 - 2015/4

UR - http://www.scopus.com/inward/record.url?scp=84989360042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989360042&partnerID=8YFLogxK

U2 - 10.1378/chest.14-1677

DO - 10.1378/chest.14-1677

M3 - Article

C2 - 25320966

AN - SCOPUS:84989360042

SN - 0012-3692

VL - 147

SP - 883

EP - 893

JO - Chest

JF - Chest

IS - 4

ER -

Executive Summary: Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this